Jun. 28 at 1:17 PM
$SLS $PFE Rise and Fall of Pfizer and perhaps Rebirth with BO of
$SLS just 1 mile away from it’s company headquarters in New York, N.Y a tiny 13 FTE Co. on the Cusp of Holy grail moment in the history of entire Biotechnology sector with A off the shelf cancer Platform GPS that delivers CURATIVE results with 0 Toxicity, mild side effects and unparalleled QOL in cancer patients.
Pfizer generated
$100 billion in revenue in 2022. Most of it came from two products tied to a global emergency Covid 19 that was ending. Albert Bourla had one window, to turn a temporary windfall into a permanent company.
Bourla took the pandemic cash and used it to buy the future of cancer treatment before the window closed. The
$43 billion acquisition of Seagen gave Pfizer a leading platform but late stage failure has cratered
$PFE Stock to near 52 week low.
$PFE with wave of patent expirations in the late 2020s need to catch the genie in the bottle once again with BO of
$SLS before bidding war starts.
✌️🙏❤️🩹 P1
